09/08/2021 | Press release | Distributed by Public on 09/09/2021 02:19
TORONTO, CANADA - (September 8, 2021) - Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15. Dan Legault, Antibe's CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company's pre-recorded presentation:
Date: Monday, Sept 13, 2021
Time: Available for on-demand viewing from 7:00 am (Eastern Time) onwards
A link to the webcast of the presentation will be available on the News & Events section of the Company's website at antibethera.com. The webcast will be available on the website for 90 days.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company's current pipeline includes three assets that seek to overcome the gastrointestinal ('GI') ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ('NSAIDs'). Antibe's lead drug, otenaproxesul, is in clinical development for the treatment of osteoarthritis pain. Additional assets include a safer alternative to opioids for peri-operative pain, and a GI-sparing alternative to low-dose aspirin. The Company's next target is inflammatory bowel disease ('IBD'), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
[email protected]